Dr. Infante on Avelumab's Potential in Ovarian Cancer

Jeffrey R. Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses the potential impact of avelumab on the treatment of patients with ovarian cancer.

An upside to treating ovarian cancer, Infante explains, is that patients often respond to several of the approved therapies. However, these are often transient responses that become less durable over time, while tumors become more refractory.

Infante discusses the potential impact of avelumab in treating this disease based off of findings from a phase Ib, open-label expansion trial, which demonstrated that the drug was well-tolerated and had complete and atypical responses in patients who had four prior lines of therapy. If further studies demonstrate similar benefit, Infante says researchers should consider moving avelumab up in treatment lines of ovarian cancer.